Arvinas (ARVN) 2022年年度报告「NASDAQ」.pdf

1、2022 Annual ReportTo Our Stockholders:In 2022,we set ambitious goals to advance our mission of improving the lives of patients with serious diseasesby pioneering therapies created with our revolutionary PROTACprotein degradation platform.I believe wehave met those goals and set the foundation for fu

2、ture growth.Throughout the year,we reported promising data across our development programs and continued progressingour broad pipeline of targets in oncology and neurology.We initiated multiple clinical trials across our oncologyprograms and continued utilizing our PROTAC Discovery Engine to expand

3、the applications of proteindegradation,with multiple programs now progressing through investigational new drug(IND)-enabling work.We are proud of the protein degradation discovery and development platform we have built at Arvinas.Clinical and Development ProgressIn November and at the San Antonio Br

4、east Cancer Congress in December,we reported positive results from thePhase 2 cohort expansion portion(VERITAC)of a Phase 1/2 trial with vepdegestrant(or ARV-471)in patientswith locally advanced or metastatic estrogen receptor(ER)-positive/human epidermal growth factor receptor 2(HER2)negative breas

5、t cancer(ER+/HER2-).Vepdegestrant targets the ER and is being co-developed withPfizer.These data continued to show a differentiated profile for vepdegestrant and reinforced its potential tobecome an important new standard of care for patients with ER+/HER2-breast cancer.We have initiated a Phase3 tr

6、ial of vepdegestrant as a monotherapy as a second-line treatment in patients with metastatic breast cancer,andwe are exploring the potential of vepdegestrant across the treatment landscape.During the year we also initiatedmultiple clinical trials with vepdegestrant,including in combination with othe